Literature DB >> 7666200

Differential expression of two vesicular monoamine transporters.

D Peter1, Y Liu, C Sternini, R de Giorgio, N Brecha, R H Edwards.   

Abstract

Specific transport proteins package classical neurotransmitters into vesicles so that their release can be regulated by neural activity. Previous studies have suggested that a single activity mediates the vesicular transport of monoamines in the adrenal gland, brain, and other tissues such as mast cells and platelets. However, molecular cloning has recently identified two vesicular transporters for monoamines. Although the predicted proteins are closely related in sequence, they show a range of differences in their physiologic and pharmacologic properties. To clarify further the biological significance of the observed functional differences, we have generated anti-peptide antibodies to the C-termini of the two transporters and used them to determine the distribution and localization of the proteins in the rat. We have detected expression of vesicular monoamine transporter 1 (VMAT1) in adrenal chromaffin cells but not in neural cells. Interestingly, some adrenal chromaffin cells also express VMAT2 but the amount of VMAT2 relative to VMAT1 appears much lower than in the bovine adrenal gland. In contrast, sympathetic ganglion cells express only VMAT2, as do enteric neurons and enterochromaffin-like cells of the stomach. Thus, although adrenal chromaffin cells, sympathetic and enteric neurons derive from the neural crest, they express different vesicular amine transporters. In the CNS, dopamine, norepinephrine, epinephrine, 5-HT, and histamine cell groups all express VMAT2. These findings are consistent with the functional characteristics of VMAT1 and VMAT2 and help to explain several classic pharmacological observations. VMAT2-immunoreactivity is generally stronger in cell bodies, proximal dendrites and axonal processes, indicating the potential for monoamine storage at each of these sites. Surprisingly, dopaminergic interneurons in the olfactory bulb show no detectable immunoreactivity for either VMAT1 or VMAT2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666200      PMCID: PMC6577657     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  83 in total

1.  Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3, 4-dihydroxyphenylalanine administration in Parkinsonian rats.

Authors:  W Y Lee; J W Chang; N L Nemeth; U J Kang
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

Review 2.  Synaptic vesicle proteins and neuronal plasticity in adrenergic neurons.

Authors:  X E Hou; A Dahlström
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

3.  Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size.

Authors:  E N Pothos; K E Larsen; D E Krantz; Y Liu; J W Haycock; W Setlik; M D Gershon; R H Edwards; D Sulzer
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

4.  SSR2(a) receptor expression and adrenergic/cholinergic characteristics in differentiated SH-SY5Y cells.

Authors:  Sayed Hossein Hashemi; Jia-Yi Li; Håkan Ahlman; Annica Dahlström
Journal:  Neurochem Res       Date:  2003-04       Impact factor: 3.996

Review 5.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 6.  Vesicular and plasma membrane transporters for neurotransmitters.

Authors:  Randy D Blakely; Robert H Edwards
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

7.  Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.

Authors:  Lucia Martiniova; Susannah Cleary; Edwin W Lai; Dale O Kiesewetter; Jurgen Seidel; Linda F Dawson; Jacqueline K Phillips; David Thomasson; Xiaoyuan Chen; Graeme Eisenhofer; James F Powers; Richard Kvetnansky; Karel Pacak
Journal:  Nucl Med Biol       Date:  2011-09-29       Impact factor: 2.408

8.  The neuronal monoamine transporter VMAT2 is regulated by the trimeric GTPase Go(2).

Authors:  M Höltje; B von Jagow; I Pahner; M Lautenschlager; H Hörtnagl; B Nürnberg; R Jahn; G Ahnert-Hilger
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

Review 9.  Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease.

Authors:  Kelly M Lohr; Shababa T Masoud; Ali Salahpour; Gary W Miller
Journal:  Eur J Neurosci       Date:  2016-09-02       Impact factor: 3.386

10.  A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles.

Authors:  Etienne A Cartier; Leonardo A Parra; Tracy B Baust; Marisol Quiroz; Gloria Salazar; Victor Faundez; Loreto Egaña; Gonzalo E Torres
Journal:  J Biol Chem       Date:  2009-11-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.